H-SAPDTRPAP-OH

Ref. 3D-PP46411

Informations sur le produit

• Nom: H-SAPDTRPAP-OH
• Synonymes: NH2-Ser-Ala-Pro-Asp-Thr-Arg-Pro-Ala-Pro-OH

Description

Peptide H-SAPDTRPAP-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-SAPDTRPAP-OH include the following: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients Y Kotera, JD Fontenot, G Pecher, RS Metzgar, OJ Finn - Cancer research, 1994 - AACRhttps://aacrjournals.org/cancerres/article-abstract/54/11/2856/499996 Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies X Pei-Xiang, J Prenzoska, IFC McKenzie - Molecular immunology, 1992 - Elsevierhttps://www.sciencedirect.com/science/article/pii/0161589092902018 T cells recognize PD (N/T) R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1 VM Pisarev , L Kinarsky, T Caffrey , FG Hanisch - International , 2005 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1567576904003224 The use of fluoroproline in MUC1 antigen enables efficient detection of antibodies in patients with prostate cancer VJ Somovilla , IA Bermejo, IS Albuquerque - Journal of the , 2017 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/jacs.7b09447 A synthetic MUC1 glycopeptide bearing betaGalNAc-Thr as a Tn antigen isomer induces the production of antibodies against tumor cells V Leiria Campo , TB Riul, L Oliveira Bortot - , 2017 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201600473 Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine V Lakshminarayanan, P Thompson - Proceedings of the , 2012 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1115166109 MUC1 vaccines, comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1, can circumvent immunoediting to control tumor growth in MUC1 V Lakshminarayanan, NT Supekar , J Wei, DB McCurry - PloS one, 2016 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145920 Glycosylated (Tn) and Anchor-Modified MUC1 Peptide Vaccines Induce Effective Anti tumor Immunity and Break Tolerance in MUC1 Transgenic Mice V Lakshminarayanan, JM Bradley, LB Pathangey - Cancer Research, 2010 - AACRhttps://aacrjournals.org/cancerres/article/70/8_Supplement/2403/562854 Immunotherapy with glycosylated and anchor-modified MUC1 peptides breaks tolerance in MUC1 transgenic mice V Lakshminarayanan, J Bradley, T Tinder, L Pathangey - Cancer Research, 2008 - AACRhttps://aacrjournals.org/cancerres/article-abstract/68/9_Supplement/2860/548576 Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. V Apostolopoulos , V Karanikas, JS Haurum - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/11/5211/30949 Peptide mimics of a tumor antigen induce functional cytotoxic T cells V Apostolopoulos , SA Lofthouse, V Popovski - Nature , 1998 - nature.comhttps://www.nature.com/articles/nbt0398-276 MUC1 peptide epitopes associated with five different H-2 class I molecules V Apostolopoulos , JS Haurum - European journal of , 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830271017 Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design V Apostolopoulos , IF McKenzie, IA Wilson - Front Biosci, 2001 - article.imrpress.comhttps://article.imrpress.com/bri/Landmark/articles/pdf/LandmarkA683.pdf Vaccine Development Against Novel Breast Cancer Antigens V Apostolopoulos , I McKenzie - 2002 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA409560 Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules V Apostolopoulos , G Chelvanayagam - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/2/767/31120 Noncanonical peptides in complex with MHC class I V Apostolopoulos , E Lazoura - Expert Review of Vaccines, 2004 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/14760584.3.2.151 MUC1-specific Cytotoxic T Lymphocytes Eradicate Tumors When Adoptively Transferred in Vivo P Mukherjee , AR Ginardi, TL Tinder, CJ Sterner - Clinical cancer , 2001 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/7/3/848s/200197 Comparative immunogenicity of a cytotoxic T cell epitope delivered by penetratin and TAT cell penetrating peptides N Brooks, S Esparon, D Pouniotis, GA Pietersz - Molecules, 2015 - mdpi.comhttps://www.mdpi.com/1420-3049/20/8/14033 Immunogenicity of a tripartite cell penetrating peptide containing a MUC1 variable number of tandem repeat (VNTR) and AT helper epitope N Brooks, J Hsu, S Esparon, D Pouniotis, GA Pietersz - Molecules, 2018 - mdpi.comhttps://www.mdpi.com/1420-3049/23/9/2233 Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells J Gong, V Apostolopoulos , D Chen, H Chen - , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2567.2000.00101.x Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1 GA Pietersz, W Li, C Osinski, V Apostolopoulos - Vaccine, 2000 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X99005150 Design of a MUC1-based cancer vaccine FG Hanisch - 2005 - portlandpress.comhttps://portlandpress.com/biochemsoctrans/article-abstract/33/4/705/65160 Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. B Agrawal, MJ Krantz, MA Reddish - International , 1998 - academic.oup.comhttps://academic.oup.com/intimm/article-abstract/10/12/1907/744541

• Marque: Biosynth